Previous reports in Hodgkin's lymphoma (HL) patients undergoing autologous hematopoietic cell transplantation (AHCT) have demonstrated a significant association between the absolute lymphocyte count at day 15 (ALC-15) with survival. To evaluate this finding further, we analyzed 146 patients with relapsed/refractory HL who underwent AHCT to evaluate the relationship between lymphocyte counts at apheresis and at two time points (days 15 and 90) after AHCT with PFS. We found no association between the ALC-15 and the ALC-90 with PFS. We found lymphocyte counts at apheresis and disease sensitive to salvage chemotherapy were predictive of PFS. In conclusion, our study does provide some support for the theory that the immune system may be important in disease control but further and more detailed studies in this area are required.
Introduction
Autologous hematopoietic cell transplant (AHCT) is the standard of care in patients with relapsed/refractory Hodgkin's lymphoma (HL) because it improves PFS over chemotherapy alone. 1 Unfortunately, up to 40% of patients relapse after AHCT. Several series have reported clinical factors that are predictive of poor outcome, including stage at relapse, 2, 3 time to relapse 2, 3 and poor performance status. 4 Recovery of PBL (40.5 Â 10 9 per liter by day 15 post-AHCT) has also been related to improved PFS and overall survival (OS) in transplanted HL patients. 5, 6 These findings have also been demonstrated in patients with other lymphoma subtypes 7 and myeloma 8 undergoing AHCT. Our study was undertaken to further evaluate the relationship between the absolute lymphocyte count (ALC) at the time of apheresis and ALC recovery at two time points after AHCT, with PFS in a group of uniformly treated patients with relapsed or refractory HL.
Methods
We evaluated 146 consecutive patients with relapsed/ refractory HL undergoing AHCT from 1999 to 2006 at our center. Patient information was retrieved from a prospectively collected database and the medical record. Patients received 2-3 cycles of salvage chemotherapy (miniBEAM (BCNU/etoposide/cytarabine/melphalan) or a platinum-based regimen), and those who had responsive (CR or PR) or stable disease (SD) as assessed by standard criteria 9 underwent stem cell mobilization with CY 2 gm/m 2 on day 1, etoposide 200 mg/m 2 on days 1-3 and filgrastim 10 mg/kg per day. Intensive therapy was melphalan 180 mg/m 2 and etoposide 60 mg/kg as previously described. 10 Filgrastim (300 mg subcutaneously) commenced on day 7 following AHCT if the absolute neutrophil count was o0.5 Â 10 9 per liter.
Statistical analysis
The primary end point was PFS. Variables analyzed with regard to PFS were age, refractory (defined as disease progression on or within 3 months of completing chemotherapy) versus relapsed disease, stage at relapse, status at transplant (CR, PR and SD), CD34 cell number infused, ALC on the first day of apheresis (pre-apheresis ALC), days 15 and 90 ALC post-AHCT (ALC-15, ALC-90), engraftment times (that is, number of days to reach an unsupported platelet count greater than 20 Â 10 9 per liter, neutrophil count greater than 0.5 Â 10 9 per liter) and infection requiring antibiotics or antiviral therapy within the first 12 months post discharge for AHCT. ALC-15 and ALC-90 values were analyzed as continuous and categorical variables. They were dichotomized at 0.5 Â 10 9 per liter and at the median based on prior reports. 8 PFS estimates were calculated using Kaplan-Meier method and compared using log-rank test. The association between PFS and ALC, ALC-15 and ALC-90 controlling for response to salvage therapy was performed using Cox proportional hazards model. A P-value of o0.05 was considered significant.
Results

Patients
Of the 146 patients analyzed, 3 were excluded due to insufficient follow-up data. The characteristics of the 143 patients analyzed are presented in Table 1 . Of them, 43% had primary refractory disease. Median CD34 cell dose infused was 7.1 Â 10 6 per kg and 94% received filgrastim post-AHCT. The median engraftment time for both platelets and neutrophils was 11 days.
Factors associated with progression-free survival After a median follow-up of 24 months, 50 patients have relapsed between 1.4 and 29.6 months post-AHCT (median 6.7 months). The 2-year OS and PFS were 94 and 60%, respectively. Status at transplant did significantly affect PFS. Those with disease responsive to salvage chemotherapy (CR or PR) had a 2-year PFS of 63 versus 42% for those with SD (hazards ratio (HR) 1.94, P ¼ 0.03). Patients with early relapsed disease (n ¼ 36, defined as relapse between 3 and 12 months of completing primary therapy) had a 2-year PFS of 56%, those who relapsed after 12 months (n ¼ 45) had a 2-year PFS of 73% (P ¼ 0.20). Patients with primary refractory disease (n ¼ 60) had a 2-year PFS of 52%, which was not significantly different from those with relapsed disease (HR 0.79, P ¼ 0.4). Stage at relapse (I/II versus III/IV) and age also did not significantly affect PFS. Patients with B symptoms at relapse (n ¼ 28) had a 2-year PFS of 49 versus 63% (n ¼ 110) for those who did not have B symptoms (HR 1.75, P ¼ 0.08). Only seven patients had a performance status of two or more at relapse.
ALC and PFS
The median ALC-15 was 0.6 Â 10 9 per liter and there was no difference in PFS for patients with ALC-15 below or above this value ( Figure 1 ) or when analyzed at a cutoff of 0.5 Â 10 9 per liter. Patients with an ALC-15 of 0.5 Â 10 9 per liter or below had 2-year PFS of 62%, versus 56% for patients with ALC-15 greater than 0.5 Â 10 9 per liter (HR 1.25, 95% confidence interval (CI) 0.66-2.36, P ¼ 0.50); and this remained nonsignificant when controlling for pre-apheresis ALC and response to salvage therapy (P ¼ 0.91). ALC-15 continued to be nonsignificant when patients with SD were excluded from the analysis (HR 1.22, 95% CI 0.64-2.35, P ¼ 0.55).
ALC-90 was available for 87 patients, 6 of these patients had relapsed on or before the ALC-90 was taken and thus were excluded from this analysis. No patient died before 90 days. We did not find a strong association between the ALC-90 and PFS (HR 0.67, 95% CI 0.42-1.06, P ¼ 0.09). Patients with ALC-90 below the median of 1.1 Â 10 9 per liter had a 2-year PFS of 64%, versus 68% for those above the median (P ¼ 0.67; Figure 2 ). When the ALC-90 was dichotomized at 0.5 Â 10 9 per liter, the 2-year PFS was 40% (P ¼ 0.11) for the 11 patients with a level on or below this and 70% (n ¼ 70) for those with a level above this (P ¼ 0.11). Again we tested ALC-90 controlling for the pre-apheresis ALC and response to salvage therapy and it remained nonsignificant (P ¼ 0.18).
In contrast, pre-apheresis ALC did appear to be correlated with PFS when analyzed as a continuous variable (HR 0.76, 95% CI 0.58-0.99, P ¼ 0.04). When dichotomized at the median of 1.2 Â 10 9 per liter patients at or above this level had a 2-year PFS of 68 versus 50% (P ¼ 0.073; Figure 3 ). The pre-apheresis ALC remained significant when controlling for response to salvage chemotherapy (P ¼ 0.031). A table of the patient characteristics dichotomized at the median pre-apheresis ALC of 1.2 Â 10 9 per liter is presented in Table 2 .
Factors associated with ALC recovery
The pre-apheresis ALC was not associated with either the ALC-15 or the ALC-90 (Spearman's correlation 0.15 and 
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Lymphocyte count in transplanted HL patients T Seshadri et al 0.24, respectively). The infused CD34 cell dose, neutrophil and platelet engraftment times were also not associated with ALC-15 or ALC-90. We did not find any relationship between the ALC 15 and ALC 90 (Spearman's correlation 0.25), and patient age did not influence ALC recovery.
Infectious morbidity
We evaluated the relationship between lymphocyte recovery and infectious morbidity post-AHCT: 33 patients (24%) had an infection in the first 12 months post discharge after AHCT-11 patients had herpes zoster and 23 patients had bacterial infections (16 respiratory tract, 5 septicemia, 1 cellulitis and 1 pneumocystis jiroveci). The 6-month probability of an infection was 21%, and patients older than the median age of 37 years were more likely to contract an infection post-AHCT-in these patients the 6-month probability for an infection was 28 versus 13% for patients aged less than 37 years (HR 2.32, 95% CI 1.1-4.9, P ¼ 0.03). Disease status (relapsed versus refractory), infused CD34 cell dose and granulocyte engraftment time did not influence the probability of developing an infection. We also analyzed ALC recovery and infectious morbidity and found that neither the ALC-15 (HR 1.06, 95% CI 0.51-2.21, P ¼ 0.88) nor the ALC-90 (HR 1.19, 95% CI 0.95-1.48, P ¼ 0.12) influenced the development of post-AHCT infections.
Discussion
Our findings contradict prior reports 5, 8 of a correlation between early lymphocyte recovery and improved PFS in patients undergoing AHCT. A recently published study Lymphocyte count in transplanted HL patients T Seshadri et al also failed to demonstrate an association between ALC-15 and PFS in patients with non-Hodgkin's lymphoma (NHL) undergoing AHCT. It is possible that the ALC-15 may be subject to confounding factors such as growth factor use, infection, transfusion and nutritional factors, which could influence short-term recovery and hamper its interpretation.
Because of these potential confounding factors, we analyzed the ALC-90 with respect to its impact on PFS. There appeared to be a stronger association between ALC-90 and PFS than the ALC-15 but statistical significance was not reached. It may be that there is a continuum of immune recovery post-AHCT and these kinetics, rather than immune function at set time points is important for disease control. Indeed, the importance of lymphocyte kinetics has been found in NHL patients undergoing AHCT. 13 A previous study 14 has demonstrated an association between the pre-apheresis ALC and the quantity of lymphocytes in the stem cell product that in turn influenced the ALC-15 value. We did not find any association between the pre-apheresis ALC and the ALC-15 nor the ALC-90. It is worthwhile to note that in our study the pre-apheresis ALC had some association with PFS, providing some support to the notion that the immune system may be important for disease control. However, because we did not perform any direct analysis of the stem cell product, the exact role of the infused lymphocytes on lymphocyte recovery cannot be directly ascertained in our study. Similar to other studies was the lack of association between the CD34 cell dose and engraftment times on ALC-15 recovery. 5, 8 Like others, 3, [15] [16] [17] we have shown that patients with chemotherapy-sensitive disease have an improved PFS compared to patients who have SD. B symptoms at relapse have been shown to be associated with PFS in several studies, 3, 18, 19 however we and others 20, 21 did not find a strong association between B symptoms at relapse and PFS. We also did not find any association between time to relapse or refractory disease and PFS, and the significance of these factors has also been variably reported in the literature. 2, [18] [19] [20] [21] [22] Immune reconstitution post-AHCT is a complex process whereby cells of the immune system recover at different rates, both in number, function and antigenetic spectrum that may influence tumor surveillance. 23 Our study that noted an association between pre-apheresis ALC and PFS does provide some support that overall immune recovery may be important in survival and that the ALC may represent a crude marker for immune reconstitution. 8 Other studies have also identified the importance of the infused lymphocyte dose in survival, 14, 24 and manipulating the stem Lymphocyte count in transplanted HL patients T Seshadri et al cell product to affect immune reconstitution may be an avenue to improve survival in patients undergoing AHCT. There are several caveats to this study; it is exploratory by design with several variables analyzed and it is a retrospective analysis. Consequently, there was no direct quantification of lymphocyte numbers or subsets infused with the cell product and ALC-90 data were available for only 87 patients. The strengths of this study are uniformity of salvage therapy, stem cell mobilization, high-dose regimen and post transplant care in the patients evaluated.
In conclusion, we found that chemotherapy-responsive disease and a higher pre-apheresis lymphocyte count were associated with PFS in patients with relapsed/refractory HL undergoing AHCT. In contrast to prior studies, 5, 7, 8, 25, 26 we did not find any association at all with ALC-15 and PFS. We are in the process of designing a prospective trial to evaluate immune reconstitution focusing on lymphocyte subsets such as naive and regulatory T cells in patients with a hematological malignancy following AHCT to better understand the biologic basis of these observations.
